From FDA labels and ClinicalTrials.gov

Are GLP-1s studied in schizophrenia and bipolar disorder?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists schizophrenia and bipolar disorder as an approved use, so prescribing one for it would be off-label. Meta-analysis of 10 randomized trials (Exenatide, liraglutide, semaglutide): In schizophrenia or bipolar disorder with cardiometabolic risk, these lowered weight by 6.17 kg and HbA1c by 0.31 points against placebo or usual care. The authors rate this low certainty. Int J Psychiatry Med, 2026 (pubmed.ncbi.nlm.nih.gov/41618880). ClinicalTrials.gov lists 14 trials of these medicines on it: 2 with posted results and 2 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 9, 2026.

Published results

What the largest trials on schizophrenia and bipolar disorder found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

Meta-analysis of 10 randomized trials

Exenatide, liraglutide, semaglutide · 665 people · Better than the comparison · Meta-analysis

In schizophrenia or bipolar disorder with cardiometabolic risk, these lowered weight by 6.17 kg and HbA1c by 0.31 points against placebo or usual care. The authors rate this low certainty.

Int J Psychiatry Med, 2026 (pubmed.ncbi.nlm.nih.gov/41618880)

The registry

Trials on schizophrenia and bipolar disorder, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide701
Liraglutide310
Exenatide210
Dulaglutide100
Tirzepatide101
Posted results

What trials on schizophrenia and bipolar disorder reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT02417142Exenatide Weekly Injections as an Adjunctive Treatment in Patients With SchizophreniaExenatidePhase 470On ClinicalTrials.gov (clinicaltrials.gov)
NCT03158805Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)LiraglutidePhase 260Percent Change in Body Weight (% change), 40 week. Active Drug: -3.3; Placebo: 0.2.
Recruiting now

Trials on schizophrenia and bipolar disorder taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (clinicaltrials.gov/study/NCT07213466)SemaglutidePhase 4Feb 1, 2029
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder (clinicaltrials.gov/study/NCT06939088)TirzepatidePhase 2Dec 31, 2028
From PubMed

Newest papers on GLP-1s and schizophrenia and bipolar disorder

  • Glucagon-like peptide-1 receptor agonists in schizophrenia spectrum disorders: A systematic review and meta-analysis of efficacy, safety and mental health outcomes (pubmed.ncbi.nlm.nih.gov/43003672)

    Meta-analysis · Br J Clin Pharmacol · Nov 9, 2026 · de Aguiar DR et al.

  • Efficacy and safety of GLP-1 receptor agonists in patients with schizophrenia spectrum disorders treated with antipsychotics: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42925811)

    Meta-analysis · Eur Neuropsychopharmacol · Oct 24, 2026 · Gędek A et al.

  • Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42920001)

    Meta-analysis · Eur J Clin Pharmacol · Oct 24, 2026 · Zhou L et al.

  • Tolerability language and gastrointestinal risk in a meta-analysis of GLP-1 receptor agonists in antipsychotic-treated schizophrenia (pubmed.ncbi.nlm.nih.gov/42893627)

    Meta-analysis · Schizophr Res · Oct 18, 2026 · Cotrik E et al.

  • Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials (pubmed.ncbi.nlm.nih.gov/42746999)

    Meta-analysis · J Psychopharmacol · Sep 16, 2026 · Moubarak ES et al.

  • Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42497473)

    Meta-analysis · Schizophr Res · Jul 24, 2026 · Sobral MVS et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

GLP-1s and schizophrenia and bipolar disorder: common questions

What did the largest trial on schizophrenia and bipolar disorder find?

Meta-analysis of 10 randomized trials (Exenatide, liraglutide, semaglutide, 665 people): In schizophrenia or bipolar disorder with cardiometabolic risk, these lowered weight by 6.17 kg and HbA1c by 0.31 points against placebo or usual care. The authors rate this low certainty.

Is any GLP-1 FDA approved for schizophrenia and bipolar disorder?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for schizophrenia and bipolar disorder?

Semaglutide, with 7 registered trials on it, then Liraglutide with 3. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for schizophrenia and bipolar disorder?

2 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.